Intensity Therapeutics, Inc.
INTS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001567264
No open-market purchases or sales by Intensity Therapeutics, Inc. insiders were filed in the last 90 days; 17 institutions reported holding it in 13F filings for Q2 2026, worth $4.79M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Intensity Therapeutics, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- +1 vs. Q4 2023
- Shares held
- 1.63M
- +1.12M (+218.5%) vs. Q4 2023
- Total value
- $8.49M
- +$4.10M (+93.3%) vs. Q4 2023
- New holders
- 6
- 9 more added
- Sold out
- 5
- 2 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INTS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 17 | $4.79M |
| Q1 2026 | 14 | $1.06M |
| Q4 2025 | 35 | $1.58M |
| Q3 2025 | 26 | $721.2K |
| Q2 2025 | 27 | $606.6K |
| Q1 2025 | 21 | $5.10M |
| Q4 2024 | 20 | $4.79M |
| Q3 2024 | 20 | $6.65M |
| Q2 2024 | 23 | $8.23M |
| Q1 2024 | 18 | $8.49M |
| Q4 2023 | 17 | $4.39M |
| Q3 2023 | 10 | $1.19M |
| Q2 2023 | 2 | $170.2K |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Intensity Therapeutics, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 7 | $0 | 0.00% | −16−69.6% | Reduced |
| Wells Fargo & Company | 2,482 | $12.9K | 0.00% | +10.0% | Added |
| UBS Group AG | 3,011 | $15.7K | 0.00% | +2,511+502.2% | Added |
| Tower Research Capital LLC (TRC) | 7,033 | $37.5K | 0.00% | +7,033 | New |
| JPMorgan Chase & Co | 8,869 | $46.1K | 0.00% | +8,829+22,072.5% | Added |
| Commonwealth Equity Services, LLC | 10,414 | $54.0K | 0.00% | +10,414 | New |
| BlackRock Inc. | 10,724 | $55.8K | 0.00% | −264−2.4% | Reduced |
| Qube Research & Technologies Ltd | 11,095 | $57.7K | 0.00% | +4,932+80.0% | Added |
| State Street Corp | 14,500 | $75.4K | 0.00% | 00.0% | Unchanged |
| Lakeview Capital Partners, LLC | 17,420 | $90.6K | 0.01% | +17,420 | New |
| Sentinus, LLC | 28,812 | $149.8K | 0.05% | +28,812 | New |
| One Charles Private Wealth Services, LLC | 31,800 | $165.4K | 0.07% | +31,800 | New |
| Mesirow Financial Investment Management, Inc. | 44,177 | $229.7K | 0.01% | +10,000+29.3% | Added |
| Geode Capital Management, LLC | 47,620 | $247.7K | 0.00% | +2,259+5.0% | Added |
| Sigma Planning Corp | 47,869 | $248.9K | 0.01% | +13,426+39.0% | Added |
| Brown Advisory Inc | 157,526 | $819.1K | 0.00% | +157,526 | New |
| Vanguard Group Inc | 177,187 | $921.4K | 0.00% | +94,118+113.3% | Added |
| Sapient Capital LLC | 1,012,069 | $5.26M | 0.12% | +812,069+406.0% | Added |
| Hohimer Wealth Management, LLC | 0 | $0 | 0.00% | −44,779−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −31,907−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −4,000−100.0% | Sold out |
| Glassman Wealth Services | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −6−100.0% | Sold out |